Adult Malignant Glioma Therapeutics Market – Snapshot

Gliomas account for more than 70% of all primary brain tumors. Glioblastoma is the most common (65%) and most malignant type of glioma. The global adult malignant glioma therapeutics market is characterized by an unmet medical need of improving survival rates. The market is witnessing rapid increase in novel pipeline drug candidates from major as well as emerging market players, supported by government policies to speed up the process of orphan drug approval. Hence, the global adult malignant glioma therapeutics market was valued at US$ 1.3 Bn in 2017 and is projected to expand at a significant CAGR of 9.2% from 2018 to 2026.

Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pipeline. The designation for orphan drug allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials along with seven years of market exclusivity upon regulatory approval. Moreover, expedited drug discovery process due to advent of high throughput technology and TCGA, and increase in discretionary funding for cancer research have led to the rise in clinical trials against malignant gliomas. However, significant attrition rate in clinical trials and staggeringly high prices of new-generation cancer drugs are the major factors likely to restrain the global adult malignant glioma therapeutics market during the forecast period.

adult-malignant-glioma-therapeutics-market.jpg

In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Glioblastoma multiforme, which accounts for 12% to 15% of all intracranial tumors and 50% to 60% of all astrocytic tumors, is likely to be the most attractive segment during the forecast period, followed by anaplastic astrocytoma. Strong research and development focus of manufacturers, presence of significant patient population driving demand for effective therapeutics to improve the overall survival rate, and rapidly increasing pipeline of innovative novel drugs are attributed to the high growth of the segment. Based on therapy, the global market has been divided into chemotherapy, targeted drug therapy, and radiation drug therapy. The chemotherapy segment has been categorized into temozolomide, bevacizumab, carmustine, and others. The targeted drug therapy segment has been segmented into EGFR inhibitors, other monoclonal antibodies, and others. The market is characterized by a unique mix of patent expirations in the chemotherapy segment and rise in new patent approvals for targeted drug therapies. Loss of market exclusivity post patent expiration and reduction in branded drug prices due to competition from generic brands are likely to result in stagnant growth rate of the chemotherapy segment compared to targeted drug therapy. The targeted drug therapy segment is likely to dominate the global adult malignant glioma therapeutics market during the forecast period. This is because the segment comprises a promising pipeline covering diverse novel techniques such as gene therapy, nucleic acid therapies, lytic viruses, stem cells, nanoparticles, and others which are able to cross the blood brain barrier and target novel inhibition points rather than focusing on the inhibition of blood vessel formation.

In terms of region, the global adult malignant glioma therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017, accounting for over 37% share in terms of revenue. Europe was another major market for adult malignant glioma therapeutics in 2017. Technological advancement is a major driver of the market in North America and Europe. However, growth of the market in the near future is likely to depend on the combined prospects in technology and opportunity in the developing countries in Asia such as China, Japan, India, and South Korea. The market in Asia Pacific is anticipated to register an above average growth rate during the forecast period owing to relatively high patient population demanding affordable care and improvement in health care infrastructure in rapidly developing countries that aid the early diagnosis of malignant gliomas.

Major players operating in the global adult malignant glioma therapeutics market include Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Arbor Pharmaceuticals, Pfizer, Inc., AbbVie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd., Teva Pharmaceutical Industries Limited, and Emcure Pharmaceuticals Limited.

Adult Malignant Glioma Therapeutics Market - Overview

This report studies the current as well as future prospects of the global adult malignant glioma therapeutics market. Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of malignant glioma therapeutics and new entrants planning to enter the market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. This section also provides the overall information and data analysis of the global adult malignant glioma therapeutics market regarding leading segments based on type, therapy, and region.

The global adult malignant glioma therapeutics market has been segmented based on type, therapy, and region. In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Based on therapy, the global market has been divided into chemotherapy, targeted drug therapy, and radiation drug therapy. The chemotherapy segment has been categorized into temozolomide, bevacizumab, carmustine, and others. The targeted drug therapy segment has been segmented into EGFR inhibitors, other monoclonal antibodies, and others.

The bottom-up approach for determining the market size was studied using various market indicators obtained from secondary sources, which include population in 2017, prevalence of all types of malignant glioma in major countries, variations in therapy cost across major regions, and approval of therapeutics in specific region. The top-down approach was used to derive the market size for therapy segments, wherein revenues of all publicly listed market players were obtained through secondary sources and analyzed for glioma specific revenues by narrowing down to revenue percentage for product segment through extensive secondary analysis of annual reports, investor presentations, press releases, primary interviews, and others. Data triangulation is based on secondary research (top-down and bottom-up approaches) and primary research. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment has been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2018 to 2026, considering 2017 as the base year.

The market overview section of the report explores market dynamics such as drivers, restraints, opportunities, and key trends that have significant impact on the global adult malignant glioma therapeutics market and could influence it in the near future. Market attractiveness analysis has been provided to explain the intensity of competition in the market across different regions. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. These factors are likely to help market players take strategic decisions to strengthen their positions and expand their shares in the global adult malignant glioma therapeutics market. The report also comprises adult malignant glioma disease overview by type, pipeline analysis, Porter’s Five Forces analysis, overview of epidemiology of glioma, snapshot of disease burden by key region / country, SWOT analysis by key therapies, regulatory scenario, reimbursement scenario, comparative analysis of available therapies & imaging landscape, and key market trends by region.

In terms of region, the global adult malignant glioma therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The report also provides market size and forecast for major countries with each product and distribution channel in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and opportunities has been provided in the overview section. This section of the report also provides the market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global adult malignant glioma therapeutics market.

Major players operating in the global adult malignant glioma therapeutics market are Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Arbor Pharmaceuticals, Pfizer, Inc., AbbVie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd., Teva Pharmaceutical Industries Limited, and Emcure Pharmaceuticals Limited.

The global adult malignant glioma therapeutics market has been segmented as follows:

Type

  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • Anaplastic Oligoastrocytoma
  • Others

Therapy

  • Chemotherapy
    • Temozolomide
    • Bevacizumab
    • Carmustine
    • Others
  • Targeted Drug Therapy
    • EGFR Inhibitors
    • Other Monoclonal Antibodies
    • Others
  • Radiation Therapy

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Adult Malignant Glioma Therapeutics Market

4. Market Overview
     4.1. Introduction
            4.1.1. Market Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics by region
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, 2016–2026
            4.4.1. Market Revenue Projections (US$ Mn)
     4.5. Porter’s Five Force Analysis, by Region

5. Market Outlook
     5.1. Adult Malignant Glioma Disease Overview
            5.1.1 Glioblastoma Multiforme
            5.1.2. Anaplastic Astrocytoma
            5.1.3. Anaplastic Oligodendroglioma
            5.1.4. Anaplastic Oligoastrocytoma
            5.1.5. Others
     5.2. Pipeline Analysis
            5.2.1. Phase III & IV Drugs Market Forecast
            5.2.1. Phase I & II Drug Candidates Comparative Analysis
     5.3. Porter’s Five Force Analysis, by Region
     5.4. Epidemiology of Glioma
            5.4.1. Prevalence, by Country
            5.4.2. Prevalence, by Type of Glioma
            5.4.3. Incidence Rate, by Country
            5.4.4. Incidence Rate, by Type of Glioma
     5.5. Disease Burden by Key Regions / Country
            5.5.1. North America
            5.5.2. Europe
            5.5.3. Asia Pacific
            5.5.4. Rest of the World
     5.6. SWOT Analysis, by Key Therapies
     5.7. Regulatory Scenario, by Key Region / Country
     5.8. Reimbursement Scenario, by Key Region / Country
     5.9. Imaging Technologies Landscape in Glioma Analysis
     5.10. Key Market Trends, by Region

6. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Type
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016– 2026
            6.3.1. Glioblastoma Multiforme
            6.3.2. Anaplastic Astrocytoma
            6.3.3. Anaplastic Oligodendroglioma
            6.3.4. Anaplastic Oligoastrocytoma
            6.3.5. Others
     6.4. Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Type

7. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Therapy
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
            7.3.1. Chemotherapy
                     7.3.1.1. Temozolomide
                     7.3.1.2. Bevacizumab
                     7.3.1.3. Carmustine
                     7.3.1.4. Others
            7.3.2. Targeted Drug Therapy
                     7.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                     7.3.2.2. Other Monoclonal Antibodies
                     7.3.2.3. Others
            7.3.3. Radiation Therapy
     7.4. Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy

8. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Region
     8.1. Key Findings
     8.2. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Region
            8.2.1. North America
            8.2.2. Europe
            8.2.3. Asia Pacific
            8.2.4. Latin America
            8.2.5. Middle East & Africa
     8.3. Market Attractiveness, by Region

9. North America Adult Malignant Glioma Therapeutics Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
     9.2. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
            9.2.1. Glioblastoma Multiforme
            9.2.2. Anaplastic Astrocytoma
            9.2.3. Anaplastic Oligodendroglioma
            9.2.4. Anaplastic Oligoastrocytoma
            9.2.5. Others
     9.3. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
            9.3.1. Chemotherapy
                     9.3.1.1. Temozolomide
                     9.3.1.2. Bevacizumab
                     9.3.1.3. Carmustine
                     9.3.1.4. Others
            9.3.2. Targeted Drug Therapy
                     9.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                     9.3.2.2. Other Monoclonal Antibodies
                     9.3.2.3. Others
            9.3.3. Radiation Therapy
     9.4. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Country, 2016–2026
            9.4.1. U.S.
            9.4.2. Canada
     9.5. Market Attractiveness Analysis
            9.5.1. By Type
            9.5.2. By Therapy
            9.5.3. By Country

10. Europe Adult Malignant Glioma Therapeutics Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
            10.2.1. Glioblastoma Multiforme
            10.2.2. Anaplastic Astrocytoma
            10.2.3. Anaplastic Oligodendroglioma
            10.2.4. Anaplastic Oligoastrocytoma
            10.2.5. Others
     10.3. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
            10.3.1. Chemotherapy
                     10.3.1.1. Temozolomide
                     10.3.1.2. Bevacizumab
                     10.3.1.3. Carmustine
                     10.3.1.4. Others
            10.3.2. Targeted Drug Therapy
                     10.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                     10.3.2.2. Other Monoclonal Antibodies
                     10.3.2.3. Others
            10.3.3. Radiation Therapy
     10.4. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
            10.4.1. Germany
            10.4.2. U.K.
            10.4.3. France
            10.4.4. Spain
            10.4.5. Italy
            10.4.6. Rest of Europe
     10.5. Europe Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
            10.5.1. By Type
            10.5.2. By Therapy
            10.5.3. By Country/Sub-region

11. Asia Pacific Adult Malignant Glioma Therapeutics Market Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
     11.2. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
            11.2.1. Glioblastoma Multiforme
            11.2.2. Anaplastic Astrocytoma
            11.2.3. Anaplastic Oligodendroglioma
            11.2.4. Anaplastic Oligoastrocytoma
            11.2.5. Others
     11.3. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
            11.3.1. Chemotherapy
                     11.3.1.1. Temozolomide
                     11.3.1.2. Bevacizumab
                     11.3.1.3. Carmustine
                     11.3.1.4. Others
            11.3.2. Targeted Drug Therapy
                     11.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                     11.3.2.2. Other Monoclonal Antibodies
                     11.3.2.3. Others
            11.3.3. Radiation Therapy
     11.4. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
            11.4.1. China
            11.4.2. Japan
            11.4.3. India
            11.4.4. Rest of Asia Pacific
     11.5. Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
            11.5.1. By Type
            11.5.2. By Therapy
            11.5.3. By Country/Sub-region

12. Latin America Adult Malignant Glioma Therapeutics Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
     12.2. Latin America Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
            12.2.1. Glioblastoma Multiforme
            12.2.2. Anaplastic Astrocytoma
            12.2.3. Anaplastic Oligodendroglioma
            12.2.4. Anaplastic Oligoastrocytoma
            12.2.5. Others
     12.3. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
            12.3.1. Chemotherapy
                     12.3.1.1. Temozolomide
                     12.3.1.2. Bevacizumab
                     12.3.1.3. Carmustine
                     12.3.1.4. Others
            12.3.2. Targeted Drug Therapy
                     12.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                     12.3.2.2. Other Monoclonal Antibodies
                     12.3.2.3. Others
            12.3.3. Radiation Therapy
     12.4. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
            12.4.1. Brazil
            12.4.2. Mexico
            12.4.3. Rest of Latin America
     12.5. Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
            12.5.1. By Type
            12.5.2. By Therapy
            12.5.3. By Country/Sub-region

13. Middle East & Africa Adult Malignant Glioma Therapeutics Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
     13.2. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
            13.2.1. Glioblastoma Multiforme
            13.2.2. Anaplastic Astrocytoma
            13.2.3. Anaplastic Oligodendroglioma
            13.2.4. Anaplastic Oligoastrocytoma
            13.2.5. Others
     13.3. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
            13.3.1. Chemotherapy
                     13.3.1.1. Temozolomide
                     13.3.1.2. Bevacizumab
                     13.3.1.3. Carmustine
                     13.3.1.4. Others
            13.3.2. Targeted Drug Therapy
                     13.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                     13.3.2.2. Other Monoclonal Antibodies
                     13.3.2.3. Others
            13.3.3. Radiation Therapy
     13.4. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
            13.4.1. GCC Countries
            13.4.2. South Africa
            13.4.3. Rest of Middle East & Africa
     13.5. MEA Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
            13.5.1. By Type
            13.5.2. By Therapy
            13.5.3. By Country/Sub-region

14. Competition Landscape
     14.1.Market Player - Competition Matrix (By Tier and Size of companies)
     14.2.Market Share Analysis, by Company (2017)
     14.3.Market Footprint Analysis
     14.4. Competitive Business Strategies
     14.5. Company Profiles
            14.5.1. Merck & Co., Inc.
                     14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.1.2. Product Portfolio
                     14.5.1.3. SWOT Analysis
                     14.5.1.4. Strategic Overview
                     14.5.1.5. Financial Overview
            14.5.2. F. Hoffmann-La Roche Ltd.
                     14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.2.2. Product Portfolio
                     14.5.2.3. SWOT Analysis
                     14.5.2.4. Strategic Overview
                     14.5.2.5. Financial Overview
            14.5.3. Arbor Pharmaceuticals
                     14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.3.2. Product Portfolio
                     14.5.3.3. SWOT Analysis
                     14.5.3.4. Strategic Overview
                     14.5.3.5. Financial Overview
            14.5.4. Pfizer, Inc.
                     14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.4.2. Product Portfolio
                     14.5.4.3. SWOT Analysis
                     14.5.4.4. Strategic Overview
                     14.5.4.5. Financial Overview
            14.5.5. AbbVie, Inc.
                     14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.5.2. Product Portfolio
                     14.5.5.3. SWOT Analysis
                     14.5.5.4. Strategic Overview
                     14.5.5.5. Financial Overview
            14.5.6. Amgen, Inc.
                     14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.6.2. Product Portfolio
                     14.5.6.3. SWOT Analysis
                     14.5.6.4. Strategic Overview
                     14.5.6.5. Financial Overview
            14.5.7. Bristol-Myers Squibb Company
                     14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.7.2. Product Portfolio
                     14.5.7.3. SWOT Analysis
                     14.5.7.4. Strategic Overview
                     14.5.7.5. Financial Overview
            14.5.8. Sun Pharmaceuticals Ltd.
                     14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.8.2. Product Portfolio
                     14.5.8.3. SWOT Analysis
                     14.5.8.4. Strategic Overview
                     14.5.8.5. Financial Overview
            14.5.9. Teva Pharmaceutical Industries Limited
                     14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.9.2. Product Portfolio
                     14.5.9.3. SWOT Analysis
                     14.5.9.4. Strategic Overview
                     14.5.9.5. Financial Overview
            14.5.10. Emcure Pharmaceuticals Limited
                     14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.10.2. Product Portfolio
                     14.5.10.3. SWOT Analysis
                     14.5.10.4. Strategic Overview
                     14.5.10.5. Financial Overview

List of Tables

Table 01: Signatures and Clinical Features of Glioblastoma (GBM) Subtypes
Table 02: Disease Burden, by Key Region/Country (1/2)
Table 03: Disease Burden, by Key Region/Country (2/2)
Table 04: Comparative Analysis of Orphan Drug Policies
Table 05: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 06: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
Table 07: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
Table 08: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
Table 09: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 10: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 11: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 12: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
Table 13: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
Table 14: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
Table 15: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 16: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 17: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
Table 18: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
Table 19: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
Table 20: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 21: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 22: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
Table 23: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
Table 24: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
Table 25: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 26: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 27: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
Table 28: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
Table 29: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
Table 30: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 31: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 32: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
Table 33: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
Table 34: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026

List of Figures

Figure 01: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 02: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Type (2017)
Figure 03: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy (2017)
Figure 04: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Region (2017)
Figure 05: Overall Survival Time of Glioblastoma Patients, by Therapy
Figure 06: Overall Survival Time of Glioblastoma Patients, by Age Group
Figure 07: Glioblastoma Patients Relative Survival Rates
Figure 08: Overall Incidence Rate of Glioma %
Figure 09: Regulatory Approval Process - U.S.
Figure 10: Regulatory Approval Process - Europe
Figure 11: Regulatory Approval Process - Japan
Figure 12: Global Adult Malignant Glioma Therapeutics Market Trends, by Region
Figure 13: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
Figure 14: Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
Figure 15: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Glioblastoma Multiforme, 2016–2026
Figure 16: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anaplastic Astrocytoma, 2016–2026
Figure 17: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anaplastic Oligodendroglioma, 2016–2026
Figure 18: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anaplastic Oligoastrocytoma, 2016–2026
Figure 19: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016–2026
Figure 20: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
Figure 21: Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018–2026
Figure 22: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Chemotherapy, 2016–2026
Figure 23: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Targeted Therapy, 2016–2026
Figure 24: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Radiation Therapy, 2016–2026
Figure 25: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Region, 2017 and 2026
Figure 26: Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Region, 2018–2026
Figure 27: North America Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 28: North America Adult Malignant Glioma Therapeutics Market Value Share (%), by Country, 2017 and 2026
Figure 29: North America Adult Malignant Glioma Therapeutics Market Attractiveness, by Country, 2018– 2026
Figure 30: North America Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
Figure 31: North America Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
Figure 32: North America Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
Figure 33: North America Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018– 2026
Figure 34: Europe Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 35: Europe Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 36: Europe Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 37: Europe Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
Figure 38: Europe Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
Figure 39: Europe Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
Figure 40: Europe Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018–2026
Figure 41: Asia Pacific Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 42: Asia Pacific Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub- region, 2017 and 2026
Figure 43: Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 44: Asia Pacific Adult Malignant Glioma Therapeutics Market Value Share (%), by Type 2017 and 2026
Figure 45: Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
Figure 46: Asia Pacific Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy 2017 and 2026
Figure 47: Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy 2018–2026
Figure 48: Latin America Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 49: Latin America Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub- region, 2017 and 2026
Figure 50: Latin America Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub- region, 2018–2026
Figure 51: Latin America Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
Figure 52: Latin America Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
Figure 53: Latin America Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
Figure 54: Latin America Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018– 2026
Figure 55 Middle East & Africa Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 56: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 57: Middle East & Africa Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 58: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
Figure 59: Middle East & Africa Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018– 2026
Figure 60: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
Figure 61: Middle East & Africa Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018–2026
Figure 62: Global Adult Malignant Glioma Therapeutics Market Share, by Company, 2017
Figure 63: AbbVie, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 64: AbbVie, Inc. Breakdown of Net Sales, by Region, 2017
Figure 65: AbbVie, Inc. Breakdown of Net Sales, by Drug, 2017
Figure 66: AbbVie, Inc. Research and Development Cost (US$ Mn), 2015–2017
Figure 67: Merck & Co., Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
Figure 68: Merck & Co., Inc. Breakdown of Net Sales, by Region, 2017
Figure 69: Merck & Co., Inc. Breakdown of Net Sales, by Business Segment, 2017
Figure 70: Merck & Co., Inc. Research & Development Cost, 2015–2017 (US$ Bn)
Figure 71: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 72: Pfizer Inc. R&D Expenses (US$ Mn), 2014–2017
Figure 73: F. Hoffmann-La Roche Ltd Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 74: F. Hoffmann-La Roche Ltd Breakdown of Net Sales, by Region, 2017
Figure 75: F. Hoffmann-La Roche Ltd Breakdown of Net Sales, by Business Segment, 2017
Figure 76: F. Hoffmann-La Roche Ltd Research & Development Cost, 2015–2017 (US$ Mn)
Figure 77: Bristol-Myers Squibb Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 78: Bristol-Myers Squibb Company Breakdown of Net Sales (%), by Region, 2017
Figure 79: Bristol-Myers Squibb Company Breakdown of Net Sales, by Product Segment, 2017
Figure 80: Bristol-Myers Squibb Company Research & Development Cost, 2015–2017 (US$ Mn)
Figure 81: Amgen, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 82: Amgen, Inc. Breakdown of Net Sales, by Region, 2017
Figure 83: Amgen, Inc. Breakdown of Net Sales, by Type of Sale, 2017
Figure 84: Amgen, Inc. Research and Development Cost (US$ Mn), 2015–2017
Figure 85: Sun Pharmaceuticals Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 86: Sun Pharmaceuticals Ltd. Breakdown of Net Sales, by Region, 2017
Figure 87: Sun Pharmaceuticals Ltd. Breakdown of Net Sales, by Product Segment, 2017
Figure 88: Sun Pharmaceuticals Ltd. Research & Development Cost (US$ Mn), 2015–2017
Figure 89: Teva Pharmaceutical Industries Limited Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 90: Teva Pharmaceutical Industries Limited Breakdown of Net Sales, by Region, 2017
Figure 91: Teva Pharmaceutical Industries Limited Breakdown of Net Sales, by Business Segment, 2017
Figure 92: Teva Pharmaceutical Industries Limited Research and Development Cost (US$ Mn), 2015–2017

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Adult Malignant Glioma Therapeutics Market